2/2 milrinone for prevention of post-patent ductus arteriosus closure syndrome in extremely preterm infants (midas trial) - DCC resubmission
Active Cooperative Agreement Awarded Last action
- Award ID
- U24HL166580
- Recipient
-
Research Triangle Institute UEI JJHCMK4NT5N3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,560,626
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 46% complete
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Infants born preterm are exposed to an array of morbidities. The most common cardiovascular problem observed in this population is patent ductus arteriosus (PDA). Following surgical closure of a PDA, infants can develop post-ligation cardiac syndrome (plcs), a serious complication which represents a state of severe postoperative cardiopulmonary instability. Plcs can be observed in up to 50% of extremely premature infants after surgical closure of the PDA. Recognition and treatment of plcs often occurs late and treatment is variable across hospitals. To date, there have been no randomized controlled clinical trials (rcts) of cardiovascular drugs to either prevent or treat plcs in preterm infants. Given the variance in treatment of plcs, the potential use of harmful treatments amid suboptimal evidence or scientifically proven justification for use, a masked, multicenter randomized trial is essential. Preliminary data suggest that milrinone, a commonly used cardiovascular medication, reduces the risk of plcs in neonates requiring surgical ligation for PDA. The proposed milrinone for prevention of post-ligation cardiac syndrome (midas) trial aims to move preliminary research forward by designing and implementing an RCT to obtain additional data to determine efficacy of prophylactic milrinone at reducing the incidence of plcs and improving neonatal outcomes. We will apply the experience and rigor of the neonatal research network infrastructure in performing randomized placebo-controlled trials in union with RTI's leadership in statistical design and analysis and numerous prior successes in the development and implementation of rcts. The specific aims for the midas trial are: • specific aim #1: determine the efficacy of prophylactic milrinone on decreasing plcs and mortality in extremely preterm infants, born at gestational age
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,166,949 | |
| Amendment | $1,221,243 | |
| Original award | $1,172,434 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Research Institute At Nationwide Children's Hospital | $75,639 | |
| Medidata Solutions, Inc. | $151,064 |
Quick answers
Who received award U24HL166580?
U24HL166580 was awarded to Research Triangle Institute by National Heart Lung and Blood Institute (National Institutes of Health) on July 1, 2024.
How much is award U24HL166580 worth?
$3,560,626 has been obligated on U24HL166580.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award